Loading
A phase 2 trial of Ciltacabtagene autoleucel, Cyclophosphamide, Fludarabine in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel is a phase 2 interventional study registered as NCT07149857 by Janssen Research & Development, LLC, with 60 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-04-12. Interventions recorded: Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy, Multiple myeloma.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy, Multiple myeloma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy.
Shares Fludarabine, Cyclophosphamide.